Acute Brain Injury ComaNCT07115459
Development and Validation of a Prognostic Model for Neurocritical Patients Using Multimodal Brain Monitoring
An observational study of Acute Brain Injury Coma and Neurocritical Care, run by Xiangya Hospital of Central South University at 1 site in China.
Trial summary
This study aims to develop and validate a prognostic model for neurocritical patients using multimodal brain monitoring data. By combining data from various monitoring techniques such as EEG, TCD, and NIRS, this model will help predict 90-day outcomes (awake, comatose, or deceased) and support personalized treatment… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Acute Brain Injury Coma, Neurocritical Care, Cerebral Infarction
- How many people
- 200 participants
- Where
- 1 siteChina
- Study dates
- 8 Jan 2024to 31 Dec 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Neurocritical patients aged 18-80 years with acute brain injury admitted to the ICU.
Who may be able to join
- Aged 18-80 years, no gender restrictions.
- Diagnosed with acute brain injury (ABI), including one of the following: large cerebral infarction, supratentorial large-volume intracerebral hemorrhage, subarachnoid hemorrhage, or severe traumatic brain injury, with imaging evidence (CT or MRI) supporting the diagnosis.
- On ICU admission, Glasgow Coma Scale (GCS) eye response = 1 (no eye opening) and motor score ≤ 5 (does not follow commands); or within 48 hours, neurological deterioration with no eye opening and motor score reduced to ≤ 5 (total GCS score ≤ 8).
- Able to undergo continuous multimodal monitoring, with an expected ICU stay of ≥72 hours.
- Informed consent signed by the family or legal representative.
Who cannot join
- Confirmed brain death on admission or imaging showing irreversible brain herniation.
- Severe trauma unrelated to brain injury (e.g., multiple fractures, spinal cord injuries, or visceral rupture) that may interfere with brain function monitoring or outcome assessment.
- Pre-existing severe neurological disorders such as epilepsy, severe encephalopathy, or chronic intracranial conditions (e.g., brain tumors or hydrocephalus).
- Inability to perform multimodal monitoring due to technical issues (e.g., equipment failure or sensor installation problems).
- Predicted survival time <24 hours after admission, or family members choose to withdraw treatment.
- Refusal to participate in the study by the patient or their legal representative.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
XiangyaHospital of Central South University
Changsha, Hunan, 410080
Zhang
About this study
Official title: Protocol for Developing and Validating a Multimodal Brain Monitoring-Based Prognostic Model for Neurocritical Patients: A Prospective, Observational, Multicenter Cohort Study
This study aims to develop and validate a prognostic model for neurocritical patients using multimodal brain monitoring data. By combining data from various monitoring techniques such as EEG, TCD, and NIRS, this model will help predict 90-day outcomes (awake, comatose, or deceased) and support personalized treatment decisions. The study is observational and involves no experimental interventions.
Read the detailed description
This study is a prospective, observational, multicenter cohort study conducted in China. It focuses on neurocritical patients with acute brain injury, including large cerebral infarction, intracranial hemorrhage, subarachnoid hemorrhage, or severe traumatic brain injury. The study will collect multimodal data from EEG, TCD, and NIRS monitoring within 1-3 days of ICU admission. Machine learning algorithms will be used to develop a model predicting 90-day outcomes, categorized as awake, comatose, or deceased. The study population includes patients aged 18-80 years. Exclusion criteria include pre-existing severe neurological disorders, incomplete monitoring data, or withdrawal during the study period.
- Conditions
- Acute Brain Injury Coma, Neurocritical Care, Cerebral Infarction, Intracranial Hemorrhages, Subarachnoid Hemorrhage, Severe Traumatic Brain Injury
- Keywords
- Multimodal Brain Monitoring, Prognostic Model
- Medical subject headings
- Cerebral Infarction, Intracranial Hemorrhages, Subarachnoid Hemorrhage, Brain Injuries, Traumatic
What is being measured
The primary outcome is the main question the study is designed to answer.
90-day Outcome Prediction
The primary outcome is the prediction of patient status at 90 days post-ICU admission, categorized as awake, comatose, or deceased.
Measured: 90-day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2025
- Study start8 Jan 2024
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Brain Injury ComaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xiangya Hospital of Central South University
- Sponsor type
- University, hospital or other
- Collaborators
- Changsha Fourth Hospital
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07115459
- Sponsor's protocol ID
- 2024070747-2
- Status last verified
- Sep 2026
- First submitted
- 3 Aug 2025
- Last updated
- 17 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There is no plan to share individual participant data (IPD) due to privacy, ethical, or regulatory considerations